Description
InformationLomustine (NSC79037, Gleostine, CeeNU, CCNU) inhibits cancer cells by damaging theDNAand stops cells from dividing.In vitroLomustine inhibits the growth of ZR-75-1 and U373 with IC50 of 12 µM and 15 µM, respectively. Lomustine reduces the level of expression of the DNA repair protein O6-alkylguanine-DNA alkyltransferase. Lomustine (420 µM) triggers apoptosis through the mitochondrial pathway via decrease in the level of the anti-apoptosis proteins Bcl-2 and Bcl-xl, respectively, in both medulloblastoma and normal human epithelial and fibroblast cells. Lomustine induces cell cycle delay in G2/M phase in medulloblastoma cells and up-regulates p21 protein level in a p53-independent manner in HFSN1 cells.In vivoLomustine can cause delayed, cumulative dose-related, chronic hepatotoxicity that is irreversible and can be fatal. Lomustine could result in infrequent severe hematological toxicity in cats with spontaneously arising tumors, and the incidence of either grade III or IV neutropenia and thrombocytopenia is 4.1% and 1.0%, respectively. Lomustine trends toward a greater likelihood for progressive neutropenia and statistically significant higher response rates in cats with spontaneously arising tumors.Cell Datacell lines：A375 cellsConcentrations：133 µMIncubation Time：1 hourPowder Purity:≥98%